MIAMI--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Shire plc has exercised its option under agreements with Noven to acquire the exclusive development rights to a new transdermal patch for ADHD to be formulated by Noven. In connection with this exercise, Noven received a $5.9 million milestone payment from Shire.
